Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Also, the very favorable safety profile demonstrated in these studies, including no neurotoxicity observed in any of the 60 patients could potentially provide a critical differentiation in early line settings and additional indications |
| The past few months have been exciting, both for Gracell and the CAR-T field at large |
| Lastly, on the manufacturer side, we believe that GC012F is positioned favorably with overnight manufacturing and enhanced sales fitness combined with our team's significant experience accumulated over the years |
| And this product I mean so far were convinced it's very robustly safe across different indications of late and early line of multiple myeloma and DLBCL, now SLE |
| This consistent track record of safety gives us confidence as we expand our studies to a new field where the standards for safety are exceptionally high |
| In short, we believe 12F is a highly differentiated candidate backed by outstanding safety record, novel and a strong scientific rationale and FastCAR-T technology as well as supported by our team's extensive experience in manufacturing and optimizing the process |
| GC012F also continued to show a favorable safety profile with around 78% patients not having CRS of any grade and no patients reporting neurotoxicity or icons |
| I am pleased to see strides, we have made in these disease areas, reflecting our dedication to addressing areas of high unmet need with cutting-edge solutions |
| We see immense opportunity here and believe 12F is ideally positioned as a potential treatment for many autoimmune conditions, including SRE, combining its safety track record, CD19 BCMA dual targeting capability and faster and consistent product delivery |
| We are very encouraged by the profile of GC012F and have high confidence that this therapy could bring profound benefits, to the patients worldwide |
| The consistent findings provide good evidence supporting our strong scientific rationale in leveraging the power of dual targeting and validating the superior qualities of FasTCAR-T cells |
| We significantly strengthened our financial position in August 2023 as we completed a private placement transaction, raising $100 million upfront and up to $50 million in additional funds, if the warrants are fully exercised within 24 months |
| This provides a very encouraging early evidence that GC012F is inducing an immune reset |
| Therefore, we feel there is a strong scientific rationale, to support targeting both BCMA and CD19, which aligns with GC012F design in order to provide a more effective and long-lasting therapeutic approach for refractory SRE |
| The progress we have made, is a testament to the entire Gracell team's relentless pursuit of innovation |
| We think these data are highly compelling suggesting a potentially ideal profile for the frontline application of CAR-T therapy, combining both deep response and high tolerability |
| FDA and will be an important milestone as we continue to advance our efforts to provide innovative and effective treatment options, to patients with autoimmune disease |
| Encouraging to hear that B-cells are recovering by three months |
| But it's very, very encouraging |
| Fast and consistent delivery of CAR-T therapy would help to shorten this period of suboptimal disease control and greatly reduce the risk of disease flare-up and additional organ damage during the wait |
| I look forward to sharing our ongoing progress and remain confident that our journey will lead to meaningful advancement in the field |
| We remain committed to pushing the boundaries of medical innovation and improving patient outcomes through our transformative therapies |
| As highlighted, we are continuing to amass clinical evidence supporting the tremendous potential of our lead candidate, BCMA/CD19 dual-targeting FasTCAR-T GC012F |
| expect, meaning predict, so far, all I can say so far so good and took time to have a meaningful efficacy data for safety, because it comes in short, coming within 15 days, you could much see them all |
| It is good to see another dual targeting CAR-T that is being applied to autoimmune disease |
| The advancement of the investigator initiative clinical study in systemic lupus, erythematosus, SLE and also release of preclinical data from our solid tumor program at a Society of Immunotherapy of Cancer, SITC Annual Meeting This period marked a crucial juncture for the CAR-T field |
| Aspirations such as rapid manufacturing, achieving a cleaner safety profile and enabling deeper, more durable responses, were shared by all company researchers and were also personal motivators for myself that led to the funding of Gracell |
| As a reminder, we have seen compelling data in the Phase 1 study with GC007g, including 100% MRD-negative CR/CRI among 9BLL patients |
| In the field of automate disease treatment, safety stands as a critical factor for defining success |
| And based on what we see today, it's very consistent |
| Statement |
|---|
| We suspended China Phase 2 trial evaluating GC007g for the treatment of B-cell acute lymphoblastic leukemia or BALL, considering the limited commercial opportunity for this niche candidate |
| The decline in net loss is primarily a result of a decrease in the fair value of warrant liabilities |
| Sorry, I missed your second part |
| Actual results could differ materially from those stated or implied by those forward-looking statements as a result of various important factors, and please refer to the Risk Factors section of our latest 20-F filings with SEC for a full disclosure of these risks and factors |
| I mean this is a very difficult to answer |
| However, we think it's important to remember, SLE is a disease in, which auto antibodies attack a patient's own tissues |
| And then final question is, I was just curious |
| And what's translating to readout is the MRD negativity |
Please consider a small donation if you think this website provides you with relevant information